Bristol-Myers Squibb's (BMY) and AbbVie's (ABBV) Elotuzumab helped patients with previously-treated multiple myeloma live for a median 33 months without the blood cancer getting worse in a Phase II trial. The drug was given with Celgene's (CELG) Revlimid and the steroid dexamethasone. Elotuzumab is also being tested in two Phase III trials for multiple myeloma. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Thu, 8:35AM)
at Benzinga.com (Wed, 12:57PM)
at CNBC.com (Feb 17, 2015)
at Investor's Business Daily (Jan 27, 2015)
at CNBC.com (Jan 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs